AVNR: Profile for Avanir Pharmaceuticals, Inc

AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the treatment of pseudobulbar affect; and a Phase III trial for the treatment of patients with diabetic peripheral neuropathic pain. The company also offers Abreva, an over-the-counter product for the treatment of cold sores. AVANIR Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California.

Key Statistics

COMPANY WEBSITES

Home Page

Search Yahoo! for:
More on Avanir Pharmaceuticals

CORPORATE GOVERNANCE

Avanir Pharmaceuticals's Corporate Governance Quotient (CGQ®) as of 1-Dec-09 is better than 69.4% of Russell 3000 companies and 73.5% of Pharmaceuticals, Biotechnology & Life Sciences companies.

Brought to you by Institutional Shareholder Services.

View Financials

KEY EXECUTIVES

	Pay	Exercised
Mr. Keith A. Katkin , 37 Chief Exec. Officer, Pres, Director and Member of Exec. Committee	N/A	N/A
Ms. Christine G. Ocampo , 36 Principal Financial Officer, VP of Fin. and Sec.	$ 233.00K	N/A
Dr. Randall E. Kaye M.D., 47 Chief Medical Officer and Sr. VP	N/A	N/A
Mr. Eric S. Benevich , 44 VP of Communications	N/A	N/A
Mr. Gregory J. Flesher , 39 VP of Bus. Devel.	N/A	N/A

Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.

View Insiders

Add to Portfolio

Set Alert

Email to a Friend

•

Annual Reports

•

Sector Analysis